Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: a prospective randomized pilot study.

scientific article published on 28 June 2011

Pitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: a prospective randomized pilot study. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.JHEP.2011.04.024
P698PubMed publication ID21718671
P5875ResearchGate publication ID51457168

P50authorDetlef SchuppanQ17418245
P2093author name stringMasahiko Shimada
Shuhei Yoshida
Ryota Masuzaki
P433issue1
P921main subjectribavirinQ421862
pegylated interferonQ7160835
chronic hepatitis CQ55779873
P304page(s)299-300
P577publication date2011-06-28
P1433published inJournal of HepatologyQ15724402
P1476titlePitavastatin enhances antiviral efficacy of standard pegylated interferon plus ribavirin in patients with chronic hepatitis C: a prospective randomized pilot study.
P478volume56

Reverse relations

cites work (P2860)
Q50550427Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C.
Q38198618Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality
Q55280981Host-targeting therapies for hepatitis C virus infection: current developments and future applications.
Q50549620Meloxicam as an adjuvant to peginterferon-α-2a and ribavirin treatment for genotype 1 chronic hepatitis C: A randomized trial.
Q36026554Metabolic disorders and steatosis in patients with chronic hepatitis C: metabolic strategies for antiviral treatments
Q37182990Statin (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor)-based therapy for hepatitis C virus (HCV) infection-related diseases in the era of direct-acting antiviral agents